Biotech ETFs Are Breaking Out on Pfizer’s Array Biopharma Deal

This article was originally published on

Biotech sector exchange traded funds rallied Monday after Pfizer (NYSE: PFE) said it would acquire Array Biopharma Inc. (NasdaqGS: ARRY) in a $10.6 billion deal to bolster its portfolio of cancer fighting drugs in face of rising competition in the generics drug space. Among the best performing non-leveraged ETFs of Monday, the ALPS Medical Breakthroughs [...]

Read more at >